Research programme: recombinant proteins - Yuhan Corporation

Drug Profile

Research programme: recombinant proteins - Yuhan Corporation

Alternative Names: YH 25348; YH 25723; YH 25724; YH-Bio1; YHbio1

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yuhan
  • Class Recombinant proteins
  • Mechanism of Action Fibroblast growth factor 21 agonists; Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis
  • No development reported Diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in South Korea (Parenteral)
  • 19 Apr 2017 Preclinical data in Non-alcoholic steatohepatitis presented at the The International Liver Congress 2017 (ILC - 2017)
  • 01 Jan 2017 Preclinical trials in Non-alcoholic steatohepatitis in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top